{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:32:08Z","timestamp":1793356328282,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2026-25476887"],"award-info":[{"award-number":["RS-2026-25476887"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2020-NR049589"],"award-info":[{"award-number":["RS-2020-NR049589"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jchromb.2026.125302","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:02:56Z","timestamp":1789495376000},"page":"125302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of an LC-MS\/MS method for the novel PROTAC KT-474 in rat and mouse plasma: Application to dose-dependent pharmacokinetics and metabolite identification in mice"],"prefix":"10.1016","volume":"1284","author":[{"given":"Ji-Hoon","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang-Khoa","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Joo","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125302_bb0005","doi-asserted-by":"crossref","first-page":"674363","DOI":"10.1155\/2010\/674363","article-title":"Targeting TLR\/IL-1R signalling in human diseases","volume":"2010","author":"Loiarro","year":"2010","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.jchromb.2026.125302_bb0010","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20061825","article-title":"A critical role for IRAK4 kinase activity in toll-like receptor\u2013mediated innate immunity","volume":"204","author":"Kim","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jchromb.2026.125302_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/BTT.S525106","article-title":"IRAK4 targeting: a breakthrough approach to combat hidradenitis suppurativa","author":"Zhang","year":"2025","journal-title":"Biologics Targets Ther."},{"key":"10.1016\/j.jchromb.2026.125302_bb0020","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/156802609789044407","article-title":"IRAK-4 inhibitors for inflammation","volume":"9","author":"Wang","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0025","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3390\/ijms21155262","article-title":"Mechanisms of action for small molecules revealed by structural biology in drug discovery","volume":"21","author":"Li","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jchromb.2026.125302_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125302_bb0040","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474 a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0045","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jchromb.2026.125302_bb0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40005-025-00771-5","article-title":"Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for glioblastoma treatment","volume":"56","author":"Patel","year":"2026","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jchromb.2026.125302_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2533\/chimia.2022.341","article-title":"Linkers as game-changers in PROTAC technology: emphasizing general trends in PROTAC pharmacokinetics for their rational design","volume":"76","author":"Cecchini","year":"2022","journal-title":"Chimia"},{"key":"10.1016\/j.jchromb.2026.125302_bb0060","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME demonstrates ARV-110\u2019s high druggability despite low oral bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2026.125302_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70181","article-title":"Pharmacokinetics and pharmacodynamics of KT-474, a novel selective interleukin-1 receptor\u2013associated kinase 4 (IRAK4) degrader, in healthy adults","volume":"18","author":"Agarwal","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2026.125302_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17145\/jab.18.010","article-title":"Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry","volume":"4","author":"Meesters","year":"2018","journal-title":"J. Appl. Bioanal."},{"key":"10.1016\/j.jchromb.2026.125302_bb0080","series-title":"Bioanalytical Method Validation M10","author":"I. Guideline","year":"2019"},{"key":"10.1016\/j.jchromb.2026.125302_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40005-024-00662-1","article-title":"Pharmacokinetics and extensive intestinal first-pass effects of apigenin and its active metabolite, apigenin-7-O-glucuronide, in rats","volume":"54","author":"Seo","year":"2024","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jchromb.2026.125302_bb0090","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jpba.2018.11.008","article-title":"Liquid chromatography\u2013tandem mass spectrometry of recombinant human extracellular superoxide dismutase (rhSOD3) in mouse plasma and its application to pharmacokinetic study","volume":"164","author":"Jeong","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125302_bb0095","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1080\/10826076.2018.1547743","article-title":"Development of a liquid chromatography-tandem mass spectrometry method for assaying cenobamate in rat plasma","volume":"41","author":"Oh","year":"2018","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jchromb.2026.125302_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40543-024-00452-2","article-title":"Development and validation of an LC\u2013MS\/MS method for the determination of BLU-945, a fourth-generation EGFR tyrosine kinase inhibitor, in rat and mouse plasma: application to a pharmacokinetic study in rats","volume":"15","author":"Oh","year":"2024","journal-title":"Journal of Analytical Science and Technology"},{"key":"10.1016\/j.jchromb.2026.125302_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40543-025-00500-5","article-title":"Development and validation of LC-MS\/MS method for tomivosertib quantification in plasma: insights into pharmacokinetics and metabolic stability","volume":"16","author":"Panthi","year":"2025","journal-title":"Journal of Analytical Science and Technology"},{"key":"10.1016\/j.jchromb.2026.125302_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2022.104462","article-title":"Bioanalytical method validation, biopharmaceutical and pharmacokinetic evaluation of GSK-650394, a serum-and glucocorticoid-regulated kinase 1 inhibitor","volume":"16","author":"Le","year":"2023","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ddr.21505","article-title":"Differential regulation of intestinal and hepatic CYP3A by 1\u03b1, 25-dihydroxyvitamin D3: effects on in vivo oral absorption and disposition of buspirone in rats","volume":"80","author":"Maeng","year":"2019","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.jchromb.2026.125302_bb0120","series-title":"Safety Testing of Drug Metabolites: Guidance for Industry","author":"U. Food, D. Administration","year":"2020"},{"key":"10.1016\/j.jchromb.2026.125302_bb0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.trac.2010.10.014","article-title":"Metabolite identification by liquid chromatography-mass spectrometry","volume":"30","author":"Prasad","year":"2011","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jchromb.2026.125302_bb0130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/jms.1610","article-title":"Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry","volume":"44","author":"Zhang","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2026.125302_bb0135","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-008-0867-7","article-title":"Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction","volume":"63","author":"Kumar","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125302_bb0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2026.125302_bb0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C] pomalidomide in humans following oral administration","volume":"71","author":"Hoffmann","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125302_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/00498250802001834","article-title":"Differences in the total body clearance of lead compounds in the rat and mouse: impact on pharmacokinetic screening strategy","volume":"38","author":"Mcintyre","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchromb.2026.125302_bb0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2885.2004.00602.x","article-title":"Volumes of distribution","volume":"27","author":"Toutain","year":"2004","journal-title":"J. Vet. Pharmacol. Ther."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:32:37Z","timestamp":1793352757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226003910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"alternative-id":["S1570023226003910"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125302","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC-MS\/MS method for the novel PROTAC KT-474 in rat and mouse plasma: Application to dose-dependent pharmacokinetics and metabolite identification in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125302"}}